Indiana University

Open enrollment across a mixed-phase pipeline

According to ClinicalTrials.gov-derived indexes, Indiana University sits in the top decile of US sponsors by registered trial count (#38 of 15,742 sponsors by registered trial count).

890 total trials 156 currently recruiting 561 completed top decile by trial count

Indiana University: 890 sponsored US clinical trials, 156 recruiting.

Indiana University sponsors 890 registered US clinical trials on ClinicalTrials.gov, 156 of them currently recruiting, and 561 completed. 104 of these trials are in Phase 3-4 (later-stage) and 126 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Alzheimer Disease, with 11 trials.

Top-decile sponsor footprint

Indiana University ranks in the top decile of sponsors by registered trial count (#38 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 43/100

561 of 688 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (81.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

890 total, page 16 of 18

COMPLETED Phase 4

A Pilot Study on the Use of Nociceptive Flexion Reflex for Fibromyalgia

NCT00965601

COMPLETED Phase 4

The Role of Vitamin D in Immune Function in Patients With Chronic Kidney Disease (CKD) Stages 3 and 4.

NCT00749736

COMPLETED NA

Using Computers to Assist in Parental Smoking Cessation in a Pediatric Setting

NCT01334216

COMPLETED NA

GABRA2 and the Pharmacokinetics of Risk for Alcoholism (GPRA)

NCT00681655

COMPLETED NA

Breathe for Hot Flashes Randomized Controlled Trial

NCT00819182

COMPLETED NA

Exploratory Study of Sunitinib Malate as a Component of Neoadjuvant Therapy for Breast Cancer

NCT00656669

TERMINATED Phase 1

Testing New Method of Analyzing MR Images

NCT00630318

COMPLETED

Perceptions Regarding Investigational Screening for Memory Problems in Primary Care

NCT00759252

COMPLETED Phase 4

A Study of Quetiapine SR (Seroquel SR) to Treat SSRI-Resistant, Comorbid Panic Disorder Patients

NCT00619892

COMPLETED NA

Interactive Computer Program or Brochure in Increasing Colorectal Cancer Screening Among African Americans

NCT00672828

COMPLETED

The Study of Ocular Hemodynamics With Glaucoma Progression

NCT01145911

COMPLETED NA

Mobile Communication Technology for Adolescents With Diabetes

NCT00605839

COMPLETED NA

Exercise-based Motivational Interviewing for Fibromyalgia

NCT00573612

COMPLETED

Investigation of the Cylex® ImmuKnow® Assay

NCT00569842

TERMINATED Phase 4

A Clinical Study Comparing the Inflammatory Response of the Ex-Press Mini Shunt to Trabeculectomy

NCT00597181

TERMINATED

Study to Evaluate the Effectiveness of Certain Selective Serotonin Reuptake Inhibitor (SSRI) Antidepressants During Pregnancy and Evaluate Newborn Outcomes

NCT00553917

COMPLETED NA

Universal Screening for Maternal Depression With the CHICA System

NCT01238614

COMPLETED NA

Universal Screening for Tuberculosis and Anemia With the CHICA System

NCT01322841

TERMINATED NA

In-Vivo Activated T-Cell Depletion to Prevent GVHD

NCT00594308

TERMINATED Phase 2

Safety Study of Gleevec® in Children With Pulmonary Hypertension

NCT00583115

COMPLETED NA

Improving Laboratory Follow-up by Delivering an Enhanced Medication List to Outpatient Physician Practices

NCT01208987

COMPLETED Phase 3

Breast Cancer Screening Via Computer V. Phone

NCT00287040

COMPLETED Phase 4

Study of Brain Response to Emotional Pictures Using a fMRI While on Duloxetine

NCT00532480

COMPLETED NA

The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients

NCT00726934

COMPLETED NA

Intradialytic Drug Removal by Short-daily Hemodialysis

NCT00596167

COMPLETED NA

Recurrent Bacterial Vaginosis and Vaginal Acidifying Gel Trial

NCT00545181

COMPLETED Phase 4

FMRI Study of Brain Response Before and After Lithium Treatment in People With Bipolar Disorder

NCT00596622

COMPLETED

Can CT Enteroclysis Predict the Outcome of Crohn's Disease

NCT00572780

COMPLETED NA

Levels of the Stat4 Alpha and Stat4 Beta Isoforms in PBMCs From Patients With Crohn's Disease and Ulcerative Colitis

NCT00586599

TERMINATED Phase 1

A Phase I Trial of Alloreactive Cell Infusion Following Transplantation of Haplotype Cells in Patients With Myeloid Malignancies

NCT00569179

COMPLETED Phase 1

Trial of Decitabine as a Sensitizer to Carboplatin in Platinum Resistant Recurrent Ovarian Cancer

NCT00477386

COMPLETED Phase 2

Medroxyprogesterone +/- Cyclophosphamide & Methotrexate in Hormone Receptor-Negative Recurrent/Metastatic Breast Cancer

NCT00577122

COMPLETED

Metabolomics-Based Detection of Colorectal Cancer

NCT00507598

COMPLETED NA

Effects of CYP2B6 Genetic Polymorphisms on Efavirenz Pharmacokinetics

NCT00668395

COMPLETED Phase 1

A Phase I Trial of Myeloablative Conditioning w/ Clofarabine and HD Busulfan for Pts w/ Refractory Heme Malignancies Undergoing Allo PBSCT

NCT00477542

COMPLETED Phase 1

Phase I Trial of Clofarabine in Combo w/ HD Etoposide & Cyclophosphamide and APBSCT for Pts w/ High-Risk or Refractory NHL

NCT00477945

COMPLETED Phase 1

A Pilot Study of VEGF Inhibition in Patients With Lymphedema Following Breast Cancer Treatment

NCT00393497

COMPLETED

Endoscopic Ultrasound Staging of Periampullary Neoplasms: Retrospective

NCT00880633

COMPLETED Phase 2

A Prospective Open-label Study of Aripiprazole in Fragile X Syndrome

NCT00420459

COMPLETED Phase 4

Endoscopic Ultrasound-guided Celiac Plexus Neurolysis (EUS-CPN)With Alcohol in Unresectable Pancreatic Cancer: a Pilot Study

NCT00578279

COMPLETED NA

Rapid Screening Phenotype Test To Evaluate CYP 2C19 Enzyme Activity Using Stable Isotope [13C]Pantoprazole

NCT00668902

COMPLETED Phase 2

Healozone Study to Evaluate the Safety and Efficacy of the Use of Ozone for Management of Dental Caries

NCT00495495

COMPLETED NA

Endoscopic Ultrasound(EUS)-Guided TRUCUT Biopsy (EUS-TCB) of Suspected Nonalcoholic Fatty Liver Disease(NAFLD.)

NCT00586313

COMPLETED

Assessment of Lung Structure and Function of Infants Born Prematurely

NCT00422305

COMPLETED NA

A Novel Positron Emission Tomography (PET) Approach to Measuring Myocardial Metabolism

NCT02563834

TERMINATED

Storage of Bile From Routine Procedures to Study Risk Factors

NCT00414843

COMPLETED NA

Cap-fitted Colonoscopy: a Randomized, Tandem Colonoscopy Study of Adenoma Miss Rates

NCT00577083

COMPLETED NA

Study of Protective Effects of Paricalcitol on Inner Layer of Vessels and Its Protective Effect on Inflammation

NCT00428246

COMPLETED Phase 3

HIV Testing & Womens Attitudes on HIV Vaccine Trials

NCT00771537

COMPLETED Phase 2

Study of Oxaliplatin Plus Bevacizumab in Germ Cell Tumor Patients

NCT00393861

← Previous Page 16 of 18 Next →

Phase Distribution

PhaseTrial count
Phase 1 56
Phase 2 70
Phase 3 28
Phase 4 76

What is open in the Indiana University pipeline

156 recruiting of 890 indexed (18% open); 561 completed (63%).

Phase mix: 104 late (III/IV) vs 126 early (I/II) (balanced across stages).

Top condition: Alzheimer Disease (11 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Indiana University: open-pipeline peers nationwide

Peers matched on 890 registered trials and 18% open enrollment, not the therapeutic-area sidebar.

Indiana University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,5002,000 5%10%15%20% Total trials Recruiting share Indiana UniversityUniversity of California, Los AngelesHoffmann-La RocheBrigham and Women's HospitalUniversity of Texas Southwestern Medical CenterEdwards LifesciencesUniversity of South FloridaVA Office of Research and DevelopmentConvaTec
Indiana University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Indiana University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 890 trials (± recruiting share)

Sponsors near 18% open enrollment (± trial volume)

What to do with this Indiana University page

890 registered trials is a research-attention snapshot, not an endorsement of Indiana University or any single study.

  • 156 of Indiana University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Alzheimer Disease is the condition Indiana University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Alzheimer Disease trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Indiana University pipeline card: 890 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.